GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study
Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025
Opening of AAC targeted for Q4 2025 at the latest
Multiple near-term value catalysts expected over next 12 months
PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study.
Clear Path Forward for LUMEVOQ® AAC Program in France
Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize the protocol of a dose-ranging study in Q3 2025.
In parallel, the Company will work with the agency to find a solution for patients who may not be included in the study but who may benefit from the AAC program. The AAC program is targeted to open in Q4 2025 at the latest.
"In the interest of clearing the way for patients to be treated with LUMEVOQ, we are pleased to have achieved this important agreement with ANSM on a clear path forward for opening patient access to LUMEVOQ in France" said Laurence Rodriguez, Chief Executive Officer of GenSight Biologics. "We are thankful for the ANSM's ongoing engagement and openness to discussion, as we work towards the shared goal of providing access to LHON patients who urgently need a safe and effective treatment."
Financing Strategy to Support Regulatory Milestones
GenSight is implementing a financing strategy to bridge operations through the opening of the AAC program and prepare for the new global Phase III clinical trial. The Company is actively pursuing various funding initiatives to support these critical regulatory milestones.
"We are working on our financing strategy to manage the bridge between now and the opening of the AAC program and the initiation of the Phase III study," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "Our focus remains on securing the resources needed to execute our regulatory strategy while exploring additional funding opportunities. "
Advancing Core Marketing Authorization Strategy
In parallel with the French AAC program developments, GenSight will continue to advance its global marketing authorization strategy:
Preparation for regulatory consultations in the US and EU
Planning for the global Phase III trial scheduled to begin in 2026, designed to meet FDA and EMA requirements
Completing the transition to a new manufacturing partner to secure reliable clinical and commercial supply
Advancing preparations for MHRA submission in the United Kingdom
During this period, the Company will actively pursue additional non-dilutive funding opportunities, including licensing arrangements outside North America and Europe and potential M&A activities.
Multiple Value Catalysts
GenSight anticipates a number of significant value-creating events in 2025-2026:
Q3 2025: Clinical trial application for focused dose-ranging study
Q4 2025: Completion of manufacturing tech transfer
Q4 2025: Opening of the AAC program
Q2 2026: Completion of Phase III trial preparations
Early H2 2026: Initiation of global Phase III clinical trial
Early H2 2026: pre-submission meeting with MHRA
Financial Position
The Company received €0.7 million of its Research Tax Credit (CIR) end of May, with the remaining €0.4 million to be paid in July 2025. Based on current operations and projections, GenSight's cash will support operations until mid-July 2025.
The Company acknowledges that current funds are insufficient to cover operational requirements for the next 12 months. The planned financing initiatives are designed to extend the cash runway and enable the initiation of the Phase III clinical trial and UK MHRA marketing application for LUMEVOQ®.
As of June 12, 2025, the number of outstanding GenSight Biologics shares was 131,466,495 ordinary shares.
Risk factors
Detailed information regarding the Company, including its business, financial information, results, perspectives and related risk factors are contained (i) in the Company's 2024 Universal Registration Document filed with the AMF on April 8, 2025 under number D.25-0234. This document, as well as other regulated information and all of the Company's press releases, can be accessed on the Company's website (www.gensight-biologics.com) and/or AMF (www.amf-france.org). The reader's attention is drawn to the risk factors related to the Company and its activities presented in chapter 3 of its 2024 URD in particular the liquidity risk presented in the chapter 3.1.1.
About GenSight Biologics
GenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010 (lenadogene nolparvovec) is in Phase III in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding product development prospects and financial projections. These statements do not constitute guarantees of future performance and involve risks and uncertainties. While the Company is actively pursuing financing solutions, regulatory requirements necessitate disclosure that material uncertainty exists regarding the Company's ability to continue as a going concern if sufficient funding cannot be secured. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in GenSight Biologics' regulatory filings with the French Autorité des Marchés Financiers. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, GenSight Biologics undertakes no obligation to update or revise the information contained in this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612867666/en/
Contacts
GenSight Biologics Chief Financial Officer Jan Eryk Umiastowski jeumiastowski@gensight-biologics.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
Perma-Pipe International Holdings, Inc. Announces First Quarter Fiscal 2025 Financial Results
By Business Wire India Published on June 14, 2025, 13:48 IST Spring, Texas, United States: The Company generated net sales of $46.7 million compared to $34.3 million in the first quarter of 2024 Income before income taxes of $7.4 million versus $2.6 million in the first quarter of 2024 Backlog of $131.1 million at April 30, 2025, compared to $63.1 million at April 30, 2024 Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the first quarter ended April 30, 2025. 'Sales for the first quarter were $46.7 million, resulting in an increase of $12.4 million, or 36.2%, compared to $34.3 million in the same quarter last year. Net income attributable to common stock of $5.0 million was an increase of $3.6 million, or 243%, compared to $1.4 million in the first quarter of the prior year,' noted President and CEO Saleh Sagr. Backlog currently stands at $131.1 million, a decrease of $7.0 million, compared to $138.1 million at January 31, 2025. However, the Company has experienced a significant increase in backlog of $68.0 million, or 108%, compared to $63.1 million at April 30, 2024. We feel encouraged with the level of backlog we have obtained, which remains more than double the level of reported backlog at the end of the first quarter last year,' Mr. Sagr continued. 'Our first quarter results represent unprecedented performance on behalf of the Company as both sales and net income attributable to common stock are the highest levels of performance in the first quarter since transitioning from MFRI to Perma-Pipe in 2017. Additionally, net income attributable to common stock during the first quarter represents approximately 55% of the Company's full year fiscal 2024 results,' noted President and CEO Saleh Sagr. 'We are pleased with the level of business activity we are experiencing in various markets, which contributed to the overall increase in sales and earnings during the first fiscal quarter. Additionally, we are very encouraged by the level of performance in both the Americas and MENA region, which produced comparable results in the first quarter,' Mr. Sagr commented. 'The strength of our first quarter results provides significant momentum heading into the remaining quarters of fiscal 2025. We feel well-positioned that the Company will continue to capitalize on this momentum and drive further participation in development plans in MENA and gain additional market share in the North America region,' Mr. Sagr concluded. First Quarter Fiscal 2025 Results Net sales were $46.7 million and $34.3 million in the three months ended April 30, 2025 and 2024, respectively. The increase of $12.4 million, or 36%, was a result of increased sales volumes in the Middle East and in North America. Gross profit was $16.7 million, or 36% of net sales, and $10.5 million, or 31% of net sales, in the three months ended April 30, 2025 and 2024, respectively. The increase of $6.2 million, was driven primarily by increased volume of activity and better margins due to product mix. General and administrative expenses were $7.7 million and $6.1 million in the three months ended April 30, 2025 and 2024, respectively. The increase of $1.6 million, was due to higher payroll expenses and professional fees in the quarter. Selling expenses remained consistent and were $1.1 million and $1.2 million in the three months ended April 30, 2025 and 2024, respectively. Net interest expense remained consistent and was $0.4 million and $0.5 million in the three months ended April 30, 2025 and 2024, respectively. Other expense remained consistent and was less than $0.1 million in the three months ended April 30, 2025 and 2024, respectively. The Company's ETR was 21% and 30% in the three months ended April 30, 2025 and 2024, respectively. The change in the ETR is due to the mix of income and loss in various jurisdictions. Net income attributable to common stock was $5.0 million and $1.4 million in the three months ended April 30, 2025 and 2024, respectively. The increase of $3.6 million, was mainly due to increased sales volumes and better project execution in the quarter. Perma-Pipe International Holdings, Inc. Perma-Pipe International Holdings, Inc. (the 'Company') is a global leader in pre-insulated piping and leak detection systems for oil and gas gathering, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, the Company has operations at fourteen locations in six countries. Forward-Looking Statements Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) fluctuations in the price of oil and natural gas and its impact on customer order volume for the Company's products; (ii) the Company's ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (iii) decreases in government spending on projects using the Company's products, and challenges to the Company's non-government customers' liquidity and access to capital funds; (iv) the Company's ability to repay its debt and renew expiring international credit facilities; (v) the Company's ability to effectively execute its strategic plan and achieve sustained profitability and positive cash flows; (vi) the Company's ability to collect a long-term account receivable related to a project in the Middle East; (vii) the Company's ability to interpret changes in tax regulations and legislation; (viii) the Company's ability to use its net operating loss carryforwards; (ix) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company's 'over-time' revenue recognition; (x) the Company's failure to establish and maintain effective internal control over financial reporting; (xi) the timing of order receipt, execution, delivery and acceptance for the Company's products; (xii) the Company's ability to successfully negotiate progress-billing arrangements for its large contracts; (xiii) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xiv) the Company's ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xv) reductions or cancellations of orders included in the Company's backlog; (xvi) risks and uncertainties specific to the Company's international business operations; (xvii) the Company's ability to attract and retain senior management and key personnel; (xviii) the Company's ability to achieve the expected benefits of its growth initiatives; (xix) the impact of pandemics and other public health crises on the Company and its operations; and (xx) the impact of cybersecurity threats on the Company's information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at and under the Investor Center section of our website ( .) The Company's fiscal year ends on January 31. Years, results, and balances described as 2025, 2024, and 2023 are for the fiscal year ended January 31, 2026, 2025, and 2024, respectively. Additional information regarding the Company's financial results for the fiscal year ended January 31, 2025, including management's discussion and analysis of the Company's financial condition and results of operations, is contained in the Company's Annual Report on Form 10-K for the fiscal year ended January 31, 2025, which will be filed with the Securities and Exchange Commission on or about the date hereof and will be accessible at and . For more information, visit the Company's website. PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share data) (Unaudited) Three Months Ended April 30, 2025 2024 Net sales $ 46,747 $ 34,321 Gross profit 16,724 10,517 Total operating expenses 8,835 7,383 Income from operations 7,889 3,134 Interest expense 406 507 Other expense 47 67 Income before income taxes 7,436 2,560 Income tax expense 1,582 770 Net income $ 5,854 $ 1,790 Less: Net income attributable to non-controlling interest 902 347 Net income attributable to common stock $ 4,952 $ 1,443 Weighted average common shares outstanding Basic 7,983 7,906 Diluted 8,079 8,056 Earnings per share attributable to common stock Basic $ 0.62 $ 0.18 Diluted $ 0.61 $ 0.18 PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) April 30, 2025 January 31, 2025 ASSETS Current assets $ 120,700 $ 108,802 Long-term assets 57,615 56,439 Total assets $ 178,315 $ 165,241 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities $ 61,751 $ 54,063 Long-term liabilities 26,459 28,073 Total liabilities 88,210 82,136 Non-controlling interests 12,238 10,967 Stockholders' equity 77,867 72,138 Total liabilities and equity $ 178,315 $ 165,241 View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Yahoo
2 hours ago
- Yahoo
French Navy's sea drone uncovers 16th-century shipwreck at record 8,200 feet depth
In a rare convergence of military technology and maritime archaeology, a French Navy underwater drone operating off the southern coast near Saint-Tropez has located the deepest shipwreck ever discovered in French territorial waters. Resting at a depth of 2,567 meters (1.5 miles or 8,200 feet), the 16th-century Italian merchant vessel, provisionally designated Camarat 4, has emerged as an exceptionally well-preserved time capsule from Renaissance maritime trade. Detected initially via sonar as an unidentified 'large object,' the wreck was later confirmed through high-definition imaging and robotic exploration. The vessel, estimated at 30 meters in length and 7 meters wide, was discovered nearly intact, its contents remarkably undisturbed. Naval authorities, in coordination with French maritime archaeologists, conducted follow-up surveys using remotely operated vehicles (ROVs), revealing a diverse and intact cargo, including nearly 200 Ligurian ceramic jugs, an anchor, iron bars, artillery pieces, and neatly stacked yellow-glazed plates resting on the seabed. Despite minor contamination from modern debris, plastic bottles, fishing nets, and beer cans, the archaeological value of the find remains unparalleled. Researchers described the Camarat 4 as a 'time capsule' from the early modern period, its preserved cargo providing direct insight into the commercial and cultural networks that connected the Italian peninsula with wider Mediterranean markets. Initial assessments indicate the ship likely originated in Liguria, northern Italy. Ceramic artifacts bearing the 'IHS' monogram, abbreviating the Greek name of Jesus, along with floral and geometric motifs, are consistent with mid-16th-century Ligurian pottery. The vessel's design and construction further suggest it belonged to the class of merchant ships operated by Ligurian or Genoese crews, often consisting of family members or men from the same village. Such vessels formed the maritime backbone of Italy's Renaissance-era trade system, regularly transporting wine, olive oil, metal, and ceramics between Italy, Corsica, and Sardinia. The metal cargo aboard Camarat 4 primarily consists of iron bars, a common secondary export on Italian merchant ships of the period. Historical records confirm that these bars were typically bundled and protected against corrosion using organic wrapping. They were offloaded and distributed on arrival to regional blacksmiths, who converted the raw metal into tools, weapons, and agricultural implements. The presence of ceramics and iron on the wreck reflects the established risk-mitigation strategies of Renaissance maritime commerce, diversifying cargo to ensure profitability regardless of market fluctuations. The Camarat 4 joins many significant shipwreck discoveries in the western Mediterranean, including the Genoese Lomellina (sunk in 1516) and the Danish Sainte-Dorothéa (1693). A recent discovery highlights the fate of larger ships like the Santo Spirito and Santa Maria di Loreto. The Ragusan galleon sank near Genoa in 1579, carrying over 2,000 tons of naval supplies. This finding is an important milestone in underwater archaeology and a strong reminder of Italy's historic maritime republics. The combination of advanced naval detection platforms and methodical archaeological assessment has enabled unprecedented access to a submerged chapter of Mediterranean history hidden beneath 2.5 kilometers of seawater for nearly five centuries.
Yahoo
2 hours ago
- Yahoo
How Elon Musk Is Reinventing Tesla's Strategy
The CEO's embrace of nascent AI technology is a shift from the company's early days when it used off-the-shelf technology for electric cars.
